The specialist cancer drug discovery and development business last week announced a Research and Co-Development Collaboration update as well as its interim results. Investor attention is currently focused on the recently submitted dual Phase 1 clinical trial applications for the Checkpoint Kinase 1 (CHK1) programme targeting lung, pancreatic and other cancers, in partnership with the CRT Pioneer Fund. We would expect a response from the UK Medicines & Healthcare products Regulatory Agency
